GlassScriptPhysician profile
Carlos Dominguez
NPI 1467440156
$4,978.63
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $628 · 2021: $2,075 · 2022: $895 · 2023: $444 · 2024: $16.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $250 · Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $249.99 |
| Food and Beverage | $211.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,243.11 | 2020-2024 | Kisqali, Piqray |
| Celgene Corporation | $323.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $318.29 | 2019-2023 | Lynparza, Keytruda |
| Pfizer INC. | $290.72 | 2019-2022 | |
| Janssen Biotech, INC. | $184.97 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $184.51 | 2019-2023 | Lynparza |
| Glaxosmithkline, LLC. | $137.51 | 2021-2022 | |
| Blueprint Medicines Corporation | $128.89 | 2021 | |
| Exelixis INC. | $128.67 | 2019-2021 | |
| Genzyme Corporation | $96.75 | 2019-2022 | |
| Eisai INC. | $88.87 | 2019-2020 | |
| Incyte Corporation | $88.08 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.19 | 2019-2022 | |
| Seagen INC. | $72.18 | 2019-2021 | |
| Daiichi Sankyo INC. | $71.59 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $70.23 | 2019 | |
| Beigene USA, INC. | $58.85 | 2022 | |
| Amgen INC. | $54.99 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $53.89 | 2019 | |
| Abbvie INC. | $43.17 | 2020-2021 | |
| Array Biopharma INC | $35.56 | 2021 | |
| Global Blood Therapeutics, INC. | $25.00 | 2022 | |
| Genentech USA, INC. | $24.67 | 2023 | Columvi, Polivy |
| Sanofi-Aventis U.S. LLC | $23.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.15 | 2020 | |
| Sobi, INC | $22.62 | 2023 | |
| Dova Pharmaceuticals | $20.22 | 2019 | |
| Adc Therapeutics America, INC. | $18.78 | 2022 | |
| Gilead Sciences, INC. | $18.20 | 2019 | |
| Rigel Pharmaceuticals, INC. | $18.12 | 2019 | |
| Kite Pharma, INC. | $17.00 | 2023 | Yescarta |
| Astellas Pharma US INC | $14.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.